WaveMan
WaveMan · Company
NVCR · Novocure Ltd
> Search tickers & screens ⌘K
LIVE
← All companies

NVCR NovoCure (NVCR) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001645113
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
123
13F, latest reported quarter

What the filings say about NVCR

Insiders, 180 days
-$939.6K net sold
8 sellers · 0% of sales under a 10b5-1 plan

NovoCure insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, NovoCure Ltd insiders sold a net $939.6K of stock across 233 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Leonard Frank X
Chief Executive Officer
SELL
2026-06-05 SECtraded 2026-06-04
34,273
$614.5K
-14.5%
Context
  • 64 earlier Form 4 trades (code P or S) here by this insider (64 sales), the last on Mar 4, 2026.
  • The trade is 7.5% of the 459,520 shares held after it.
  • 7 other insiders sold within 30 days.
  • 123 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Leonard Frank X sold about $614.5K of NVCR on Jun 4, 2026; 7 other insiders sold within 30 days and 123 funds added in the latest 13F quarter.
LEUNG GABRIEL
Director
SELL
2026-06-03 SECtraded 2026-06-02
2,945
$46.4K
-20.0%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jun 3, 2025.
  • The trade is 3.3% of the 89,499 shares held after it.
  • 7 other insiders sold within 30 days.
  • 123 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director LEUNG GABRIEL sold about $46.4K of NVCR on Jun 2, 2026; 7 other insiders sold within 30 days and 123 funds added in the latest 13F quarter.
Stafford Kristin
Director
SELL
2026-06-03 SECtraded 2026-06-02
2,945
$46.4K
-20.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 3, 2025.
  • The trade is 26.0% of the 11,324 shares held after it.
  • 7 other insiders sold within 30 days.
  • 123 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Stafford Kristin sold about $46.4K of NVCR on Jun 2, 2026; 7 other insiders sold within 30 days and 123 funds added in the latest 13F quarter.
Ocean Allyson J
Director
SELL
2026-06-03 SECtraded 2026-06-02
2,945
$46.4K
-20.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 3, 2025.
  • The trade is 26.0% of the 11,324 shares held after it.
  • 7 other insiders sold within 30 days.
  • 123 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Ocean Allyson J sold about $46.4K of NVCR on Jun 2, 2026; 7 other insiders sold within 30 days and 123 funds added in the latest 13F quarter.
Scannell Timothy J
Director
SELL
2026-06-03 SECtraded 2026-06-02
2,945
$46.4K
-20.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jun 3, 2025.
  • The trade is 20.6% of the 14,288 shares held after it.
  • 7 other insiders sold within 30 days.
  • 123 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Scannell Timothy J sold about $46.4K of NVCR on Jun 2, 2026; 7 other insiders sold within 30 days and 123 funds added in the latest 13F quarter.
233 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 228 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$939.6K over 180 days
below 61% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
123 funds bought in last quarter
more than 68% of Medical Devices
Revenue
+8.3% year over year
below 54% of Medical Devices
Margin
-20.8% net margin
below 53% of Medical Devices
Buybacks
no share repurchases reported
Short interest
13.3% of the float short (float per yahoo 2026-10-27) · 7.7 days to cover · settled 2026-10-15
more than 91% of Medical Devices
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 8 in the prior 90
Why it matters
The absence is the signal: 8 sales in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch NVCR

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+3.4%12M
-28%-4%+20%+44%2025-102025-122026-022026-042026-062026-082026-10 2026-03-03 · DOYLE WILLIAM F sold $646.6K2026-06-04 · Leonard Frank X sold $614.5K2026-03-05 · Paravasthu Mukund sold $595.5K2026-03-03 · DOYLE WILLIAM F sold $286.5K2026-02-27 · Leonard Frank X sold $133.0K2026-02-27 · Weinberg Uri sold $103.3K2026-03-02 · Leonard Frank X sold $97.6K2026-03-04 · Weinberg Uri sold $85.3K2026-03-04 · Brackmann Christoph sold $85.3K2026-03-04 · Leonard Frank X sold $74.6K2026-03-04 · Paravasthu Mukund sold $71.6K2026-06-02 · LEUNG GABRIEL sold $46.4K2026-06-02 · Stafford Kristin sold $46.4K2026-06-02 · Ocean Allyson J sold $46.4K2026-06-02 · Scannell Timothy J sold $46.4K2026-06-02 · HILLEMAN JERYL L sold $46.4K2026-06-02 · VERNON W ANTHONY sold $46.4K2026-06-02 · Hung David sold $46.4K2026-03-02 · Weinberg Uri sold $43.6K2026-02-27 · Paravasthu Mukund sold $21.2K2026-02-27 · Puri Michal Nath sold $19.7K2026-03-04 · Leupin Nicolas sold $14.6K2026-03-04 · Puri Michal Nath sold $14.6K2026-02-27 · Leupin Nicolas sold $14.1K2026-03-02 · Paravasthu Mukund sold $5.5K2026-07-23 · NICOLAS LEUPIN filed to sell $608.6K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns NVCR: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
17,373,078 sh
$263.2M
BlackRock, Inc.
13,413,699 sh
$203.2M
Soleus Capital Management, L.P.
9,913,401 sh
$150.2M
VANGUARD PORTFOLIO MANAGEMENT LLC
6,272,490 sh
$95.0M
VANGUARD CAPITAL MANAGEMENT LLC
4,903,633 sh
$74.3M

Congress trades in NVCR

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

NVCR planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
NICOLAS LEUPIN
Filed 2026-07-23
$608.6K

NVCR mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Global X HealthTech ETF
$329.8K position · as of 2026-05-31
1.3%
ROBO Global Healthcare Technology and Innovation ETF
$901.5K position · as of 2026-07-31
1.3%
Invesco Dorsey Wright Healthcare Momentum ETF
$1.4M position · as of 2026-07-31
0.6%
Invesco NASDAQ Future Gen 200 ETF
$96.3K position · as of 2026-05-31
0.5%
Global X Aging Population ETF
$392.4K position · as of 2026-05-31
0.5%
NORTH SQUARE DYNAMIC SMALL CAP FUND
$2.8M position · as of 2026-05-31
0.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
9 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 2
0 active
2
Phase 3
0 active
5
Not applicable
2 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Novocure Inc. Pac (A.K.A. Novocure Pac)
Cycle 2026 · $160K spent
$125.9K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Mr. Danziger
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$1.5M
$796.2K
$5.4M
-65%
+18%
2023
$1.5M
-$5.2M
$5.5M
-82%
+19%
2022
$2.3M
$2.1M
$6.5M
-13%
+14%
2021
$1.2M
-$31.5M
$5.7M
-11%
+26%
2020
$9.0M
$53.3M
$7.4M
+105%
+26%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $939.6K sold by insiders over 180 days, 123 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

NVCR financials

Revenue growth
+8.3%
XBRL, annual
Net margin
-20.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$699.2M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-21.2%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$25.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.58x
long-term debt only, 2025-12-31 (6 months older than the period end); equity 2026-06-30
Cash flow to debt
-0.01x
TTM operating cash flow over long-term debt only, 2025-12-31 (6 months older than the period end)
Return on equity
-43.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-14.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-28.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$1.8B
market value at close 2026-10-26 on 2026-07-17 shares, plus long-term debt only, 2025-12-31 (6 months older than the period end), minus cash 2026-06-30
FCF yield
-1.5%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$655.4M$605.2M$509.3M$537.8M
Gross profit$488.5M$468.0M$381.1M$423.0M
Operating income-$153.8M-$170.5M-$232.9M-$89.5M
Net income-$136.2M-$169.0M-$207.0M-$93.0M
EPS (diluted)-1.22-1.56-1.95-0.88
Operating cash flow-$49.0M-$26.4M-$73.3M$30.8M
Cash$93.5M$163.8M$240.8M$115.3M
Long-term debt$195.0M$97.3M$568.8M$565.5M
SEC XBRL, fiscal years, as known on 2026-10-28

NVCR Stock Sonar score 6/7 axes

Find similar shapesCompare

NVCR ranks highest on institutional and government (74th percentile) and risk and compliance (68th), and lowest on insider conviction (18th), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
44
Inputs
  • Return on equity-43.2% · 41 pct, sector of 183
  • Return on assets-14.6% · 50 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-28.8% · 41 pct, sector of 188
Financial health
44
Inputs
  • Debt to equity0.58x · 35 pct, sector of 159
  • Cash flow to debt-0.01x · 52 pct, sector of 150
Growth
46
Inputs
  • Revenue growth, YoY+8.3% · 46 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
18
Inputs
  • Net Form 4 buying (codes P and S), 180d-$940K · 36 pct, sector of 140
  • Insider buyers, 180d0 · 0 pct, sector of 142
Institutional and government
74
Inputs
  • Funds adding, latest quarter123 · 68 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$1.1M · 80 pct, sector of 50
Risk and compliance
68
Inputs
  • Short interest, % of float+13.3% · 11 pct, sector of 241
  • Recalls per $1B revenue, 3y0.00 per $1B · 100 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+2.1% · 93 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

NVCR filings, in plain words

Are NovoCure insiders buying or selling NVCR?

In the 180 days to 2026-10-28, NovoCure insiders were net sellers, a net $939.6K across purchases and sales reported on Form 4, by 8 sellers.

Read the full summary

In the 180 days to 2026-10-28, NovoCure insiders were net sellers of NVCR, a net $939.6K across purchases and sales reported on Form 4 by 8 sellers. None of the 8 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies